deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT02211131

Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma

A Phase 2, Multicenter, Randomized, Open-label Trial Assessing the Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB to IVM1a Melanoma

Sponsor: Amgen

Conditions Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma
Interventions Immediate surgical resection of melanoma lesion(s) Talimogene Laherparepvec
Updated 18 times since 2017 Last updated: May 9, 2023 Started: Feb 3, 2015 Primary completion: Apr 30, 2019 Completion: Apr 28, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02211131, this PHASE2 trial focuses on Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma and remains completed. Sponsored by Amgen, it has been updated 18 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Jul 2017 · 3 months · monthly snapshot~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Nov 2018 · 4 months · monthly snapshot~Nov 2018 – ~Jun 2019 · 7 months · monthly snapshot~Jun 2019 – ~Nov 2019 · 5 months · monthly snapshot~Nov 2019 – ~May 2020 · 6 months · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshot~Jan 2021 – ~Jan 2022 · 12 months · monthly snapshot~Jan 2022 – ~Jun 2022 · 5 months · monthly snapshot~Jun 2022 – ~Jul 2023 · 13 months · monthly snapshot~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jul 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jun 2022 — Jul 2023 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 13 earlier versions

  1. Jan 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE2

  2. Jan 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE2

  3. Jun 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  4. May 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE2

  5. Nov 2019 — May 2020 [monthly]

    Active Not Recruiting PHASE2

  6. Jun 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE2

  7. Nov 2018 — Jun 2019 [monthly]

    Active Not Recruiting PHASE2

  8. Jul 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE2

  9. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE2

  10. Jul 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  11. Apr 2017 — Jul 2017 [monthly]

    Recruiting PHASE2

  12. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE2

  13. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Feb 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Amgen
Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Athens, Greece , Barretos, Brazil , Birmingham, United States , Chapel Hill, United States , Chur, Switzerland , Columbus, United States , Dallas, United States , Daytona Beach, United States , Dijon, France , Duarte, United States and 33 more locations